Metagenomi, Inc.
MGX
$1.67
$0.159.87%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 52.30M | 55.08M | 55.93M | 47.26M | 44.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.30M | 55.08M | 55.93M | 47.26M | 44.76M |
| Cost of Revenue | 109.18M | 110.77M | 111.35M | 105.71M | 94.40M |
| Gross Profit | -56.88M | -55.69M | -55.42M | -58.45M | -49.65M |
| SG&A Expenses | 32.02M | 32.78M | 33.06M | 31.13M | 28.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 141.20M | 143.55M | 144.42M | 136.84M | 123.25M |
| Operating Income | -88.90M | -88.47M | -88.49M | -89.59M | -78.49M |
| Income Before Tax | -83.57M | -75.53M | -73.27M | -71.44M | -60.23M |
| Income Tax Expenses | -5.51M | -1.58M | 1.73M | 5.83M | 8.03M |
| Earnings from Continuing Operations | -78.06 | -73.95 | -75.00 | -77.27 | -68.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -78.06M | -73.95M | -75.00M | -77.27M | -68.26M |
| EBIT | -88.90M | -88.47M | -88.49M | -89.59M | -78.49M |
| EBITDA | -83.49M | -83.33M | -83.55M | -84.95M | -74.29M |
| EPS Basic | -2.62 | -7.66 | -12.97 | -14.21 | -17.76 |
| Normalized Basic EPS | -1.58 | -4.33 | -7.42 | -8.23 | -10.05 |
| EPS Diluted | -2.62 | -7.66 | -12.97 | -14.21 | -17.76 |
| Normalized Diluted EPS | -1.58 | -4.33 | -7.42 | -8.23 | -10.05 |
| Average Basic Shares Outstanding | 131.84M | 97.93M | 64.57M | 36.44M | 18.70M |
| Average Diluted Shares Outstanding | 131.84M | 97.93M | 64.57M | 36.44M | 18.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |